{
    "clinical_study": {
        "@rank": "56918", 
        "acronym": "Primavera", 
        "arm_group": [
            {
                "arm_group_label": "BMI \u2265 30"
            }, 
            {
                "arm_group_label": "BMI \u226527 kg/m2 associated with DM2"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to summarize the data on efficacy and safety of Reduxine\n      administration in the routine clinical practice according to the approved indications."
        }, 
        "brief_title": "The PRIMAVERA Study: Reduxine Safety Monitoring in Patients With Alimentary Obesity", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Alimentary Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "detailed_description": {
            "textblock": "Secondary objectives:\n\n        -  to study the structure of the population of patients with the diet induced obesity with\n           body mass index (BMI) 30 kg/m2 or diet induced obesity with BMI \u226527 kg/m2 associated\n           with type 2 diabetes mellitus in respect of comorbidities and concomitant treatment to\n           determine the areas for further investigations.\n\n        -  to introduce the elements of control of adverse cardiovascular risks into the routine\n           clinical practice: questionnaire concerning enrollment criteria for Reduxine treatment\n           initiation, algorithm of Reduxine administration and treatment efficacy and safety\n           monitoring (assessment schedule).\n\n        -  to assess the effects of the treatment of overweight and obesity with Reduxine on\n           patients' quality of life parameters.\n\n      The Time Frame: the follow up of the study patients will be performed during six month to\n      one year. Exception - premature discontinuation from the study.\n\n      The scheduled visits of the patients to the investigational centres are: Week0 (inclusion of\n      the patient), Week 2, 4, 6, 8, 10, 12, 16, 20, 24, 36 and Week 48."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women of 18-60 years of age to whom, in the doctor's opinion, the on-label\n             use of Reduxine is indicated.\n\n          -  Patient's desire and ability to participate in the program and fulfill the doctor's\n             instructions designed to achieve the treatment goal and the program requirements\n             compliance.\n\n          -  Signed informed consent form for participation in the program.\n\n        Exclusion Criteria:\n\n        - Patients under age of 18 or older than 60;\n\n        Current or the history of:\n\n          -  coronary artery disease (e.g. angina, myocardial infraction);\n\n          -  congestive heart failure;\n\n          -  tachycardia;\n\n          -  peripheral arterial occlusive disease;\n\n          -  arrythmia;\n\n          -  Uncontrolled arterial hypertension >145/90 mm Hg;\n\n          -  Hypersensitivity  to sibutramine or any components of Reduxine\u00ae;\n\n          -  Current use of monoamineoxidase inhibitors (IMAO) or their use within the last 2\n             weeks;\n\n          -  Current use of other central acting weight reducing drugs or their use within the\n             last 2 weeks;\n\n          -  Use on other drugs affecting the central nervous system (e.g. antidepressants,\n             neuroleptics); tryptophan-containing drugs indicated for sleep disturbance;\n\n          -  Severe eating disorder (anorexia nervosa or bulimia);\n\n          -  Mental disease;\n\n          -  Gilles de la Tourette syndrome (generalized tics);\n\n          -  Body mass index \u226430 kg/m2 or \u226427 kg/m2 in the presence of concomitant diseases\n             (dyslipidemia,  diabetes);\n\n          -  Organic cause of obesity (e.g. hypothyrosis);\n\n          -  Thyrotoxicosis;\n\n          -  Sever liver and/or kidney function abnormality;\n\n          -  Benign prostatic hyperplasia;\n\n          -  Phaeochromocytoma;\n\n          -  Narrowangle glaucoma;\n\n          -  Documented pharmacologic, drug or alcohol addiction;\n\n          -  Pregnancy and lactation;\n\n          -  Refusal to sign the informed consent form for participation in the program;\n\n          -  Participation in a clinical study of any new drug product within 90 days prior to the\n             screening visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Men and women of 18-60 years old, in the random gender and demographical proportion, with\n        the diagnosed overweight (BMI \u2265 27 and < 30) and obesity (BMI \u2265 30)."
            }
        }, 
        "enrollment": {
            "#text": "100000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773733", 
            "org_study_id": "PROMOMED-PRIMAVERA"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Moscow", 
                    "country": "Russian Federation", 
                    "state": "Moscow region", 
                    "zip": "299090"
                }, 
                "name": "Promomed Llc"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_groups": "2", 
        "official_title": "All-Russia Non-interventional Program of Reduxine Safety Monitoring for Weight Reduction in Patients With Alimentary Obesity in the Routine Clinical Practice", 
        "overall_contact": {
            "email": "ematkevich@promo-med.ru", 
            "last_name": "Elena Matkevich, Dr.", 
            "phone": "+79262967781"
        }, 
        "overall_contact_backup": {
            "email": "ygagarina@promo-med.ru", 
            "last_name": "Yulia Gagarina, Dr.", 
            "phone": "+79258092247"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "RUSSIAN FEDERATION:   Ministry of Public Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "weight reduction, kg", 
            "safety_issue": "No", 
            "time_frame": "Dec 2014"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773733"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Heart Rate, bpm", 
                "safety_issue": "Yes", 
                "time_frame": "Dec 2014"
            }, 
            {
                "measure": "Blood pressure, mmHg", 
                "safety_issue": "Yes", 
                "time_frame": "Dec 2014"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Dec 2014"
            }
        ], 
        "source": "Promomed, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Promomed, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}